Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Translation01:31

Translation

17.4K
Translation is the process of synthesizing proteins from the genetic information carried by messenger RNA (mRNA). Following transcription, it constitutes the final step in the expression of genes. This process is carried out by ribosomes, complexes of protein and specialized RNA molecules. Ribosomes, transfer RNA (tRNA), and other proteins produce a chain of amino acids—the polypeptide—as the end product of translation.
Translation Produces the Building Blocks of Life
Proteins are...
17.4K
Translation01:31

Translation

154.8K
Lesson: Translation
Translation is the process of synthesizing proteins from the genetic information carried by messenger RNA (mRNA). Following transcription, it constitutes the final step in the expression of genes. This process is carried out by ribosomes, complexes of protein and specialized RNA molecules. Ribosomes, transfer RNA (tRNA), and other proteins produce a chain of amino acids—the polypeptide—as the end product of translation.
Translation Produces the Building Blocks of...
154.8K
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

1.6K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Explainable Multimodal Retinal Optical Imaging for Clinical Parkinson's Disease Classification Using Fundus Photography and OCT-Derived Features.

Photodiagnosis and photodynamic therapy·2026
Same author

Eating Disorders and Parkinson's Disease-1: Comorbidities, Neurobiology, and Family History.

European eating disorders review : the journal of the Eating Disorders Association·2026
Same author

Translation and psychometric validation of the Persian version of amyotrophic lateral sclerosis cognitive behavioral screen (ALS-CBS) and revised amyotrophic lateral sclerosis functional rating scale (ALSFRS-R).

Current journal of neurology·2026
Same author

Factors influencing accelerated progression in behavioral variant frontotemporal dementia.

Journal of neurology·2026
Same author

Perrault Syndrome Presenting With Progressive Ataxia and the Hot Cross Bun Sign.

Movement disorders clinical practice·2026
Same author

Comparative study of refractive errors between patients with Parkinson's disease versus age- and sex-matched healthy controls.

BMC neurology·2026

Related Experiment Video

Updated: Jan 4, 2026

Translational Brain Mapping at the University of Rochester Medical Center: Preserving the Mind Through Personalized Brain Mapping
13:12

Translational Brain Mapping at the University of Rochester Medical Center: Preserving the Mind Through Personalized Brain Mapping

Published on: August 12, 2019

46.2K

Frontrunner in Translation: Progressive Supranuclear Palsy.

Ali Shoeibi1, Nahid Olfati1, Irene Litvan2

  • 1Department of Neurology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

Frontiers in Neurology
|November 8, 2019
PubMed
Summary

Progressive supranuclear palsy (PSP) is a tau proteinopathy. Research advances in PSP diagnosis, pathology, and tau-targeting therapies are accelerating its translation, potentially benefiting other neurodegenerative diseases.

Keywords:
biomarkerepidemiologyetiopathogenesisprogressive supranuclear palsytauopathytranslational research

More Related Videos

Xenopus laevis as a Model to Identify Translation Impairment
10:24

Xenopus laevis as a Model to Identify Translation Impairment

Published on: September 27, 2015

11.0K
Real-Time Fluorescent Measurement of Synaptic Functions in Models of Amyotrophic Lateral Sclerosis
08:59

Real-Time Fluorescent Measurement of Synaptic Functions in Models of Amyotrophic Lateral Sclerosis

Published on: July 16, 2021

3.0K

Related Experiment Videos

Last Updated: Jan 4, 2026

Translational Brain Mapping at the University of Rochester Medical Center: Preserving the Mind Through Personalized Brain Mapping
13:12

Translational Brain Mapping at the University of Rochester Medical Center: Preserving the Mind Through Personalized Brain Mapping

Published on: August 12, 2019

46.2K
Xenopus laevis as a Model to Identify Translation Impairment
10:24

Xenopus laevis as a Model to Identify Translation Impairment

Published on: September 27, 2015

11.0K
Real-Time Fluorescent Measurement of Synaptic Functions in Models of Amyotrophic Lateral Sclerosis
08:59

Real-Time Fluorescent Measurement of Synaptic Functions in Models of Amyotrophic Lateral Sclerosis

Published on: July 16, 2021

3.0K

Area of Science:

  • Neuroscience
  • Neuropathology
  • Translational Medicine

Background:

  • Progressive supranuclear palsy (PSP) is characterized by abnormal tau protein deposition, a hallmark shared with other neurodegenerative conditions like Alzheimer's disease (AD).
  • Unlike AD, which has historically focused on amyloid pathology, PSP is a primary tauopathy with strong clinical-pathologic correlation and rapid progression, making it a key target for tau-focused therapeutic research.
  • Advances in understanding PSP are expected to have broader implications for treating related tauopathies.

Purpose of the Study:

  • To review recent progress in the diagnosis, epidemiology, and pathology of PSP.
  • To explore hypothesized etiopathogenesis and emerging biomarkers for PSP.
  • To summarize disease-modifying therapeutic strategies currently under development for PSP.

Main Methods:

  • Review of current literature on PSP diagnosis and epidemiology.
  • Analysis of pathological findings and proposed etiopathogenesis.
  • Evaluation of identified biomarkers and therapeutic approaches.

Main Results:

  • PSP is a distinct tauopathy with significant clinical-pathologic correlation.
  • Novel diagnostic and therapeutic strategies are emerging.
  • Translational research in PSP is advancing rapidly.

Conclusions:

  • PSP research is at the forefront of tau-targeted therapeutic development.
  • Progress in PSP is anticipated to yield benefits for patients with other tau proteinopathies.
  • The comprehensive review highlights PSP's potential as a model for neurodegenerative disease translation.